AU2008317953B2 - Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals - Google Patents

Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals Download PDF

Info

Publication number
AU2008317953B2
AU2008317953B2 AU2008317953A AU2008317953A AU2008317953B2 AU 2008317953 B2 AU2008317953 B2 AU 2008317953B2 AU 2008317953 A AU2008317953 A AU 2008317953A AU 2008317953 A AU2008317953 A AU 2008317953A AU 2008317953 B2 AU2008317953 B2 AU 2008317953B2
Authority
AU
Australia
Prior art keywords
antibody
hair
animal
delivery system
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008317953A
Other languages
English (en)
Other versions
AU2008317953A1 (en
Inventor
Rainer Fischer
Hans-Juergen Hamann
Stefan Hofmann
Stefan Schillberg
Helga Schinkel
Simon Oliver Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of AU2008317953A1 publication Critical patent/AU2008317953A1/en
Assigned to BAYER ANIMAL HEALTH GMBH reassignment BAYER ANIMAL HEALTH GMBH Request for Assignment Assignors: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH Request for Assignment Assignors: BAYER ANIMAL HEALTH GMBH
Application granted granted Critical
Publication of AU2008317953B2 publication Critical patent/AU2008317953B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008317953A 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals Ceased AU2008317953B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021396 2007-11-02
EP07021396.2 2007-11-02
PCT/EP2008/009110 WO2009056280A1 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Publications (2)

Publication Number Publication Date
AU2008317953A1 AU2008317953A1 (en) 2009-05-07
AU2008317953B2 true AU2008317953B2 (en) 2014-03-20

Family

ID=40157719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008317953A Ceased AU2008317953B2 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Country Status (9)

Country Link
US (1) US20110263826A1 (enExample)
EP (1) EP2207806B1 (enExample)
JP (1) JP5386499B2 (enExample)
KR (2) KR20100102103A (enExample)
CN (1) CN101910198B (enExample)
AU (1) AU2008317953B2 (enExample)
CA (1) CA2704024C (enExample)
NZ (1) NZ585004A (enExample)
WO (1) WO2009056280A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550863A1 (de) 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
US5597386A (en) * 1992-12-08 1997-01-28 Kanebo, Ltd. Hair coloring composition comprising anti-hair antibodies immobilized on coloring materials, and hair coloring methods
US6123934A (en) * 1994-03-24 2000-09-26 Kao Corporation Hair cosmetic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2978245B2 (ja) * 1990-03-05 1999-11-15 マリンクロット ベタリナリイ，インコーポレイテッド 寄生虫防除組成物ならびにその製造法および使用法
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
US7067499B2 (en) * 2002-05-06 2006-06-27 Hercules Incorporated Cationic polymer composition and its use in conditioning applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
US5597386A (en) * 1992-12-08 1997-01-28 Kanebo, Ltd. Hair coloring composition comprising anti-hair antibodies immobilized on coloring materials, and hair coloring methods
US6123934A (en) * 1994-03-24 2000-09-26 Kao Corporation Hair cosmetic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Paluzzi, S. 2004 Textile Res. J. vol. 74, no. 5, pp. 458-464 *

Also Published As

Publication number Publication date
JP2011502178A (ja) 2011-01-20
NZ585004A (en) 2012-04-27
US20110263826A1 (en) 2011-10-27
CN101910198B (zh) 2014-10-29
AU2008317953A1 (en) 2009-05-07
CN101910198A (zh) 2010-12-08
JP5386499B2 (ja) 2014-01-15
EP2207806A1 (en) 2010-07-21
HK1151300A1 (en) 2012-01-27
KR20150138405A (ko) 2015-12-09
CA2704024A1 (en) 2009-05-07
WO2009056280A8 (en) 2010-06-10
EP2207806B1 (en) 2013-04-10
WO2009056280A1 (en) 2009-05-07
KR20100102103A (ko) 2010-09-20
CA2704024C (en) 2016-05-31

Similar Documents

Publication Publication Date Title
JP7606518B2 (ja) 抗ｃｃｒ８抗体及びその使用
DE60220719T2 (de) Antikörper gegen das muc18-antigen
Zaman et al. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin
JP6018753B2 (ja) Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
CN102641503A (zh) 血管生成素样4蛋白抑制剂，组合，以及其用途
KR20120083534A (ko) 클로스트리듐 디피실리 독소에 대한 항체 및 이의 용도
AU2008317953B2 (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
US20140199314A1 (en) Methods and compositions for regulating iron homeostasis by modulation of bmp-6
JP6073239B2 (ja) 抗原隠蔽剤としての使用のための、ヒトラクトフェリン誘導ペプチド
Ye et al. Activities of venom proteins and peptides with possible therapeutic applications from bees and WASPS
AU2020202611A1 (en) Binding moieties for biofilm remediation
US5736141A (en) Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
Kitchener et al. Immunocontraception of Eastern Grey kangaroos (Macropus giganteus) with recombinant brushtail possum (Trichosurus vulpecula) ZP3 protein
HK1151300B (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
KR20230024289A (ko) 혈관 누출을 치료하기 위한 방법 및 조성물
O’Connor et al. Pharmacokinetics of Systemic Drug Delivery
Stocki et al. Blood-brain barrier transport using a high-affinity, brain-selective VNAR (Variable Domain of New Antigen Receptor) antibody targeting transferrin receptor 1
CN113498349A (zh) 用于治疗狂犬病毒属病毒感染的抗体和方法
Koerselman et al. Characterization of single domain antibodies that target IL-1R and ef-fectively block IL-1 signaling as a potential DMOAD
US20230364259A1 (en) Kidney targeted delivery of drugs
BA et al. C REL
JP2025536316A (ja) ウマｉｌ－５に対する抗体および抗体誘導体
Jones Phage-GnRH Constructs for Population Control of Feral Animals: Evaluation in Cats

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BAYER ANIMAL HEALTH GMBH

Free format text: FORMER APPLICANT(S): BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

PC1 Assignment before grant (sect. 113)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER APPLICANT(S): BAYER ANIMAL HEALTH GMBH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired